Company Overview
Vicarious Surgical Inc. is a specialized entity within the healthcare sector that focuses on the development and sale of single-port surgical robots for the United States market. The company's primary product, the Vicarious Surgical System, functions by virtually transporting surgeons inside a patient, thereby facilitating the performance of invasive procedures with advanced robotic assistance. Operating within the medical devices industry, the firm maintains a lean organizational structure with a total employee count of 26, reflecting the capital-intensive nature of early-stage biotechnology and robotics development. The company currently holds a market capitalization of $5.06M, while its reported annual revenue is unavailable in the provided financial data, indicating a stage of operation where traditional sales metrics may not yet be fully realized or disclosed. This limited market cap and the absence of reported revenue figures suggest that the company is likely in a growth or pre-profitability phase, where valuation is driven more by technological potential and pipeline prospects than by current cash flow generation or established sales volume.
Financial Health
The company reports a net income of $-50,182,000 and an EBITDA of $-49,543,000, while specific revenue figures are not available in the current dataset; the substantial gap between the unavailable revenue number and the significant negative net income reveals a cost structure where operating expenses are the primary driver of financial results rather than gross margin compression. Vicarious Surgical Inc. reports a free cash flow of $-26,117,000, which indicates that the company is currently burning cash to fund its operations and research, thereby limiting its immediate financial flexibility for external expansion without additional capital raising. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, suggesting that at this stage of development, the company has not yet achieved positive profitability on its sales or operations. On the balance sheet, the company holds $9.79M in cash against $7.79M in debt, resulting in a debt-to-equity ratio of 79.16, which indicates a leveraged position relative to equity but suggests sufficient liquidity to cover immediate obligations. The current ratio stands at 2.97, a metric that indicates strong short-term liquidity as the company holds nearly three times the value of current assets compared to its current liabilities. Return on equity is listed at -177.5% and return on assets is -73.0%, metrics that reveal that management has not yet generated positive returns on the capital invested in the firm, a common characteristic for biotech firms prior to commercial product launch or widespread adoption.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable (N/A) due to the lack of net income, whereas the forward P/E is listed as -0.33, a figure that implies the market expects earnings to remain negative in the near term rather than anticipating an immediate turnaround to profitability. The price-to-book ratio is 0.51, indicating that the market values the company at significantly less than its book value, which often occurs when intangible assets or future potential are not fully captured on the balance sheet. The price-to-sales ratio is not available (N/A), and the EV/EBITDA stands at -0.06, suggesting that traditional valuation multiples are distorted by the company's negative earnings and that investors are relying on alternative metrics or qualitative factors to assess value. Regarding price volatility, the stock has traded between a 52-week high of $13.75 and a 52-week low of $0.27, and without the specific current share price provided in the facts, the exact percentage distance from the high or low cannot be calculated, but the wide range demonstrates extreme historical price variance. The beta value is 1.55, which explains that the stock price is expected to be more volatile than the broader market, moving 1.55 times as much as the market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there are no historical data points available to determine whether earnings are growing faster or slower than revenue, as the company has not yet established a track record of positive earnings or consistent revenue reporting. For non-dividend payers, Vicarious Surgical Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company reinvests all available earnings or cash reserves back into the business rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical growth metrics and a complete absence of dividend income, reflecting a strategy focused on capital allocation toward product development and market entry rather than shareholder distributions.